ReviewBioMed research international2016
MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?
Review in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Prognostic Value of MicroRNAs in Patients after Myocardial Infarction: A Substudy of PRAGUE-18.Disease markers · 2019Trial
- Correlation analysis between the expression of serum microRNA-665 and the degree of coronary artery stenosis and major adverse cardiovascular events in patients with acute myocardial infarction.Journal of cardiothoracic surgery · 2024Article
- Diagnostic and prognostic significance of miR-320a-3p in patients with chronic heart failure.BMC cardiovascular disorders · 2024Article
- Clinical relevance of circulating non-coding RNAs in metabolic diseases: Emphasis on obesity, diabetes, cardiovascular diseases and metabolic syndrome.Genes & diseases · 2023Review
- MicroRNAs as a Potential Biomarker in the Diagnosis of Cardiovascular Diseases.Medicina (Kaunas, Lithuania) · 2023Review
- Leucocyte-derived micro-RNAs as candidate biomarkers in Brugada syndrome.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- Long-Term Sports Practice and Atrial Fibrillation: An Updated Review of a Complex Relationship.Journal of cardiovascular development and disease · 2023Review
- miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction-Added Value over Left Ventricular Myocardial Work Indices.Diagnostics (Basel, Switzerland) · 2022Article
- Genetic Variants ofGenes · 2022Article
- MicroRNAs in Acute ST Elevation Myocardial Infarction-A New Tool for Diagnosis and Prognosis: Therapeutic Implications.International journal of molecular sciences · 2021Review
- Recent Highlights of Research on miRNAs as Early Potential Biomarkers for Cardiovascular Complications of Type 2 Diabetes Mellitus.International journal of molecular sciences · 2021Review
- Nourin-Dependent miR-137 and miR-106b: Novel Early Inflammatory Diagnostic Biomarkers for Unstable Angina Patients.Biomolecules · 2021Article
- MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally induced cardiomyopathies.ESC heart failure · 2021Article
- Inhibition of miR-155 Attenuates Detrimental Vascular Effects of Tobacco Cigarette Smoking.Journal of the American Heart Association · 2020Article
- Article
- Vaping Cardiovascular Health Risks: an Updated Umbrella Review.Current emergency and hospital medicine reports · 2020Review
- Core-Shell Polymer-Based Nanoparticles Deliver miR-155-5p to Endothelial Cells.Molecular therapy. Nucleic acids · 2019Article
- Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 2: Pluridisciplinary perspective on their genetic and molecular origins.Journal of molecular and cellular cardiology · 2019Review
- The Biological Mechanisms of Action of Cardiac Progenitor Cell Therapy.Current cardiology reports · 2018Review
- MicroRNAs as biomarkers for clinical studies.Experimental biology and medicine (Maywood, N.J.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) and its complication remain the leading cause of mortality in industrialized countries despite great advances in terms of diagnosis, prognosis, and treatment options. MicroRNAs (miRNAs), small noncoding RNAs, act as posttranscriptional gene expression modulators and have been implicated as key regulators in several physiological and pathological processes linked to CAD. Circulating miRNAs have been evaluated as promising novel biomarkers of CAD, acute coronary syndromes, and acute myocardial infarction, with prognostic implications. Several challenges related to technical aspects, miRNAs normalization, drugs interaction, and quality reporting of statistical multivariable analysis of the miRNAs observational studies remain unresolved. MicroRNA-based therapies in cardiovascular diseases are not ready yet for human trials but definitely appealing. Through this review we will provide clinicians with a concise overview of the pros and cons of microRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.